Alcon seen down after sales miss, tighter outlook
** Shares in Swiss eye-care group Alcon ALCC.S are seen down about 4% in pre-market trading after Q3 sales missed expectations and the company tightened its 2026 outlook
** Q3 sales rise 5% to $2.72 billion, slightly missing LSEG analyst consensus of $2.74 billion
** Vontobel calls the results "mixed", citing weak Implantables performance despite strong Consumables growth, and expects Implantables weakness to weigh on shares
** Implantables sales fall 2% amid continued US competition, partly offset by strong international growth
** Alcon expects around 6% sales growth, 100-150 bps of core margin expansion and 12%-14% earnings growth this year; it provided wider ranges previously
** Shares were down about 2% YTD at Tuesday's close